ELAC2 and prostate cancer: Prostate cancer developed in both models when the mutations were bred on the transgenic adenocarcinoma of mouse prostate (TRAMP) background, implicating ELAC2 mutations as susceptibility factors for prostate cancer in the presence of additional genetic insults.